NCT03761875Active, not recruiting
NK Cell Deregulation in HBV Patients
Source: ClinicalTrials.gov · Last updated 26 Jun 2026
Brief summary (registry, in English)
Natural Killer (NK) cells play a large role in the innate immune response as they are equipped to kill infected or tumor cells. They express a panel of activating and inhibitory receptors that regulate the destruction of the target cell. Many reports have shown that NK cell function is suppressed in CHB patients. Exhaustion occurs when activating receptors become over stimulated leading to the loss of NK function. The investigators hypothesize that NK cells are rendered dysfunctional/ exhausted by HBV. The primary objective is to determined the phenotypical modifications and mechanisms associated to NK cell dysfunction, during different phases of CHB infection, in not treated patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 12 Nov 2018
- Start date
- 11 Dec 2018
- Primary completion date
- 11 Nov 2026
- Lead sponsor
- University Hospital, Limoges
- Diseases
- Hepatitis B
- NCT number
- NCT03761875
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 11 Dec 2018 to the primary completion date, 11 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
- Chronic liver disease of a non-HBV etiology
- Immune or cancerous disease
Other
- Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
Who the study is looking for
- Patients must meet all of the following inclusion criteria to be eligible for participation in this study:
- Male or female, age ≥18 years
- HBV infection or chronic HBV infection
- Willing and able to provide written informed consent
- Healthy donors must meet all of the following inclusion criteria to be eligible for participation in this study:
- Male or female, age between 18 and 50 years
- Willing and able to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Limoges Hospital Coordinator of this site? Confirm its status | Limoges | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.